CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in two upcoming investor conferences.
Jefferies Healthcare Conference
Fireside Chat
Date: Thursday, June 8, 2023
Time: 8:30 a.m. ET
Goldman Sachs 44th Annual Global Healthcare Conference
Fireside Chat
Date: Wednesday, June 14, 2023
Time: 2:40 p.m. PT / 5:40 p.m. ET
Live webcasts of the fireside chats will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. Archived replays will be available on the same website for approximately 90 days.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
Contact: Eva Stroynowski 617.949.4370 estroynowski@omegatx.com
